vs
EyePoint, Inc.（EYPT）与HARVARD BIOSCIENCE INC（HBIO）财务数据对比。点击上方公司名可切换其他公司
HARVARD BIOSCIENCE INC的季度营收约是EyePoint, Inc.的38.3倍（$23.7M vs $619.0K）。HARVARD BIOSCIENCE INC净利率更高（-12.0% vs -10922.3%，领先10910.3%）。HARVARD BIOSCIENCE INC同比增速更快（-3.3% vs -94.7%）。HARVARD BIOSCIENCE INC自由现金流更多（$-545.0K vs $-66.0M）。过去两年HARVARD BIOSCIENCE INC的营收复合增速更高（-1.6% vs -77.0%）
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
EYPT vs HBIO — 直观对比
营收规模更大
HBIO
是对方的38.3倍
$619.0K
营收增速更快
HBIO
高出91.3%
-94.7%
净利率更高
HBIO
高出10910.3%
-10922.3%
自由现金流更多
HBIO
多$65.5M
$-66.0M
两年增速更快
HBIO
近两年复合增速
-77.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $619.0K | $23.7M |
| 净利润 | $-67.6M | $-2.8M |
| 毛利率 | — | 59.7% |
| 营业利润率 | -11364.3% | 7.2% |
| 净利率 | -10922.3% | -12.0% |
| 营收同比 | -94.7% | -3.3% |
| 净利润同比 | -63.3% | -15916.7% |
| 每股收益（稀释后） | $-0.82 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EYPTHBIO
| Q4 25 | $619.0K | $23.7M | ||
| Q3 25 | $966.0K | $20.6M | ||
| Q2 25 | $5.3M | $20.4M | ||
| Q1 25 | $24.5M | $21.8M | ||
| Q4 24 | $11.6M | $24.6M | ||
| Q3 24 | $10.5M | $22.0M | ||
| Q2 24 | $9.5M | $23.1M | ||
| Q1 24 | $11.7M | $24.5M |
净利润EYPTHBIO
| Q4 25 | $-67.6M | $-2.8M | ||
| Q3 25 | $-59.7M | $-1.2M | ||
| Q2 25 | $-59.4M | $-2.3M | ||
| Q1 25 | $-45.2M | $-50.3M | ||
| Q4 24 | $-41.4M | $18.0K | ||
| Q3 24 | $-29.4M | $-4.8M | ||
| Q2 24 | $-30.8M | $-2.9M | ||
| Q1 24 | $-29.3M | $-4.7M |
毛利率EYPTHBIO
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 58.4% | ||
| Q2 25 | — | 56.4% | ||
| Q1 25 | — | 56.0% | ||
| Q4 24 | — | 57.1% | ||
| Q3 24 | 93.0% | 58.1% | ||
| Q2 24 | 85.2% | 57.2% | ||
| Q1 24 | 93.5% | 60.3% |
营业利润率EYPTHBIO
| Q4 25 | -11364.3% | 7.2% | ||
| Q3 25 | -6420.8% | 1.0% | ||
| Q2 25 | -1166.8% | -4.0% | ||
| Q1 25 | -199.7% | -228.1% | ||
| Q4 24 | -390.4% | 0.0% | ||
| Q3 24 | -311.2% | -8.5% | ||
| Q2 24 | -364.5% | -9.0% | ||
| Q1 24 | -285.2% | -9.3% |
净利率EYPTHBIO
| Q4 25 | -10922.3% | -12.0% | ||
| Q3 25 | -6183.4% | -6.0% | ||
| Q2 25 | -1114.3% | -11.2% | ||
| Q1 25 | -184.8% | -231.2% | ||
| Q4 24 | -357.3% | 0.1% | ||
| Q3 24 | -279.0% | -21.9% | ||
| Q2 24 | -325.3% | -12.7% | ||
| Q1 24 | -250.6% | -19.1% |
每股收益（稀释后）EYPTHBIO
| Q4 25 | $-0.82 | $-0.06 | ||
| Q3 25 | $-0.85 | $-0.03 | ||
| Q2 25 | $-0.85 | $-0.05 | ||
| Q1 25 | $-0.65 | $-1.14 | ||
| Q4 24 | $-0.65 | $0.01 | ||
| Q3 24 | $-0.54 | $-0.11 | ||
| Q2 24 | $-0.58 | $-0.07 | ||
| Q1 24 | $-0.55 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.1M | $8.6M |
| 总债务越低越好 | — | $35.9M |
| 股东权益账面价值 | $306.1M | $13.7M |
| 总资产 | $364.0M | $80.1M |
| 负债/权益比越低杠杆越低 | — | 2.61× |
8季度趋势，按日历期对齐
现金及短期投资EYPTHBIO
| Q4 25 | $306.1M | $8.6M | ||
| Q3 25 | $204.0M | $6.8M | ||
| Q2 25 | $255.7M | $7.4M | ||
| Q1 25 | $318.2M | $5.5M | ||
| Q4 24 | $370.9M | $4.1M | ||
| Q3 24 | $253.8M | $4.6M | ||
| Q2 24 | $280.2M | $4.0M | ||
| Q1 24 | $299.3M | $4.3M |
总债务EYPTHBIO
| Q4 25 | — | $35.9M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $34.9M | ||
| Q1 25 | — | $36.4M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $34.9M | ||
| Q2 24 | — | $35.7M | ||
| Q1 24 | — | $35.6M |
股东权益EYPTHBIO
| Q4 25 | $306.1M | $13.7M | ||
| Q3 25 | $200.2M | $14.1M | ||
| Q2 25 | $246.0M | $15.7M | ||
| Q1 25 | $298.4M | $14.8M | ||
| Q4 24 | $336.5M | $63.3M | ||
| Q3 24 | $218.7M | $65.3M | ||
| Q2 24 | $228.3M | $67.2M | ||
| Q1 24 | $249.9M | $68.8M |
总资产EYPTHBIO
| Q4 25 | $364.0M | $80.1M | ||
| Q3 25 | $251.7M | $78.0M | ||
| Q2 25 | $301.1M | $80.1M | ||
| Q1 25 | $362.6M | $79.8M | ||
| Q4 24 | $418.5M | $126.6M | ||
| Q3 24 | $300.9M | $131.2M | ||
| Q2 24 | $324.2M | $128.9M | ||
| Q1 24 | $329.2M | $133.2M |
负债/权益比EYPTHBIO
| Q4 25 | — | 2.61× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | 2.45× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-65.0M | $-96.0K |
| 自由现金流经营现金流 - 资本支出 | $-66.0M | $-545.0K |
| 自由现金流率自由现金流/营收 | -10667.7% | -2.3% |
| 资本支出强度资本支出/营收 | 159.3% | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-243.4M | $5.5M |
8季度趋势，按日历期对齐
经营现金流EYPTHBIO
| Q4 25 | $-65.0M | $-96.0K | ||
| Q3 25 | $-59.4M | $1.1M | ||
| Q2 25 | $-62.6M | $2.8M | ||
| Q1 25 | $-53.1M | $3.0M | ||
| Q4 24 | $-35.8M | $1.7M | ||
| Q3 24 | $-39.0M | $-842.0K | ||
| Q2 24 | $-20.2M | $-846.0K | ||
| Q1 24 | $-31.2M | $1.4M |
自由现金流EYPTHBIO
| Q4 25 | $-66.0M | $-545.0K | ||
| Q3 25 | $-60.2M | $877.0K | ||
| Q2 25 | $-63.8M | $2.7M | ||
| Q1 25 | $-53.4M | $2.5M | ||
| Q4 24 | $-36.2M | $1.4M | ||
| Q3 24 | $-40.6M | $-1.7M | ||
| Q2 24 | $-21.1M | $-1.7M | ||
| Q1 24 | $-32.4M | $758.0K |
自由现金流率EYPTHBIO
| Q4 25 | -10667.7% | -2.3% | ||
| Q3 25 | -6226.9% | 4.3% | ||
| Q2 25 | -1196.5% | 13.0% | ||
| Q1 25 | -218.4% | 11.4% | ||
| Q4 24 | -312.7% | 5.8% | ||
| Q3 24 | -385.8% | -7.8% | ||
| Q2 24 | -222.4% | -7.2% | ||
| Q1 24 | -277.0% | 3.1% |
资本支出强度EYPTHBIO
| Q4 25 | 159.3% | 1.9% | ||
| Q3 25 | 82.6% | 1.0% | ||
| Q2 25 | 22.9% | 0.4% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 3.3% | 1.2% | ||
| Q3 24 | 15.0% | 4.0% | ||
| Q2 24 | 9.5% | 3.5% | ||
| Q1 24 | 10.2% | 2.6% |
现金转化率EYPTHBIO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 95.83× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EYPT
暂无分部数据
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
